You are here:

Archived: maraviroc (Celsentri)

Advice

Following a full submission

maraviroc (Celsentri) as 150 mg and 300mg tablets is not recommended for use within NHS Scotland in combination with other antiretroviral medicinal products, for treatmentexperienced adult patients infected with only CCR5-tropic HIV-1 detectable.

When added to optimised background therapy, maraviroc was associated with a significant reduction in viral load compared with addition of placebo in heavily pre-treated patients. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: maraviroc (Celsentri)
SMC Drug ID: 458/08
Manufacturer: Pfizer Ltd
Indication: In combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 April 2008

Current Advice

Resubmission 13 October 2008

Back